Supplemental information for PAR-16-357
Office of the Director
Program Announcements
- Biomedical Knowledgebase (U24 - Clinical Trials Not Allowed) PAR-20-097
- NIDA Program Project Grant Applications (P01 Clinical Trial Optional) PAR-19-345
- NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) PAR-19-258
- Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed) PA-18-876
Request for Applications
Notices
Chemistry Pharmacology Branch
Program Announcements
- Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed) PAR-19-039
- Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional) PAR-19-040
- BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR) (R43/R44 - Clinical Trial Not Allowed) PA-18-871
- BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR) (R41/R42 - Clinical Trials Not Allowed) PA-18-870
- Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional) PAR-18-657
- Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional) PAR-18-527
- Assay development and screening for discovery of chemical probes or therapeutic agents (R01) PAR-17-438
- Discovery of in vivo Chemical Probes for Novel Brain Targets (R01) PAR-17-336
Notices
Genetics, Epigenetics and Development Branch
Program Announcements
- NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) PAR-20-267
- Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) PAR-20-225
- Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) PAR-20-224
- NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional) PAR-20-221
- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed) PAR-20-147
- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed) PAR-20-148
- NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) PAR-19-259
- Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed) PAR-18-789
- Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional) PAR-18-437
Request for Applications
- BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed) RFA-DA-21-006
- Using Human Cell Animal Chimera Brains to Study HIV Latency and Pathology R01 - Clinical Trials Not Allowed RFA-DA-21-026
- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed) RFA-DA-21-019
- Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional) RFA-DA-21-005
Notices of Special Interest (NOSI)
- Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience NOT-DA-20-022 - R01,R21
- Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes NOT-DA-20-018 - R01,R03,R21,333
- Notice of Special Interest (NOSI): Effects of Cannabis Use and Cannabinoids on the Developing Brain NOT-DA-20-039 - R01,R03,R21
- Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders NOT-DA-20-030 - R01,P50,P01
- Notice of Special Interest (NOSI): Transcriptomic, epigenomic, regulatory RNA or functional genomic research in Substance Use Disorders NOT-DA-20-031 - R01,R03,R21,333,R21/R33
- Notice of Special Interest (NOSI): Modeling Social Contagion of Substance Use Epidemics NOT-DA-20-009 - R01,R03,R21
- Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse Research NOT-DA-19-041 - R01,R21,R03
Notices
Behavioral Cognitive Neuroscience Branch
Program Announcements
- Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional) PAR-19-310
- Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) PAR-19-282
- Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional) PA-19-200
- Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional) PA-19-201
- Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed) PAR-19-162
- Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed) PAR-19-163
- Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional) PAR-18-918
- Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01 Clinical Trial Optional) PA-18-603
- Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 ) PAR-18-510
- Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional ) PAR-18-509
- Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) PAR-18-227
Request for Applications
- The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional) RFA-OD-19-029
- Tobacco Regulatory Science (R01 Clinical Trial Optional) RFA-OD-19-028
- Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research (R21 Clinical Trial Not Allowed) RFA-OD-19-021
- Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed) RFA-OD-19-022
Notices
- Notice of Additional Funds Available for PAS-18-624, " Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01- Clinical Trial Optional)" NOT-DA-18-048
- Notice of Additional Funds Available for PAS-18-625, " Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional)" NOT-DA-18-049
Integrative Neuroscience Branch
Program Announcements
- Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed) PAR-20-182
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) PAR-18-746
- Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional) PA-18-060
- Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional) PA-18-078
- Imaging the Persistent HIV Reservoir (R01) PA-17-305
- HIV-1 infection of the Central Nervous System (R01) PA-17-100
Notices
- BRAIN Initiative: Notice of Support for Research on the Fundamental Neurobiology of Endogenous Opioid Systems NOT-DA-18-046
- Notice of Change to the Open Date in PA-18-917, " Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional) NOT-DA-18-044
- Notice of Change to the Eligibility of Foreign Components in PA-18-060, " Neuroscience Research on Drug Abuse (R01)" NOT-DA-18-042
- Notice of Change to the Eligibility of Foreign Components in PA-18-078, " Neuroscience Research on Drug Abuse (R21)" NOT-DA-18-043